The Cost of Keytruda: Understanding the Co-Pay
What is Keytruda?
Keytruda, also known as pembrolizumab, is a medication used to treat various types of cancer, including melanoma, lung cancer, kidney cancer, and others. It is a type of immunotherapy that works by helping the body's immune system fight cancer cells.
The Cost of Keytruda
The cost of Keytruda can be a significant burden for patients. According to a report by DrugPatentWatch.com, the average wholesale price (AWP) of Keytruda in the United States is around $12,500 per month. However, the actual cost to patients can be much higher, depending on various factors such as insurance coverage, co-pay, and other out-of-pocket expenses.
Co-Pay Assistance Programs
To help make Keytruda more affordable, Merck, the manufacturer of the medication, offers a co-pay assistance program. This program helps eligible patients pay for their co-pay, which can range from $10 to $20 per prescription, depending on the patient's insurance coverage.
Eligibility for Co-Pay Assistance
To be eligible for co-pay assistance, patients must meet certain criteria, including:
* Being a resident of the United States
* Having commercial insurance that covers Keytruda
* Not being eligible for government programs such as Medicare or Medicaid
* Not being able to afford the co-pay without assistance
How to Apply for Co-Pay Assistance
Patients can apply for co-pay assistance through the Merck Patient Assistance Program website or by calling 1-877-888-4231. The application process typically takes a few days to a week to complete.
Other Options for Affording Keytruda
In addition to co-pay assistance, there are other options for patients who are struggling to afford Keytruda. These include:
* Patient Assistance Programs (PAPs): Some pharmaceutical companies, including Merck, offer PAPs that provide free or discounted medication to eligible patients.
* Non-Profit Organizations: Organizations such as the Cancer Financial Assistance Coalition (CFAC) and the Patient Access Network (PAN) Foundation offer financial assistance to patients with cancer.
* Government Programs: Patients who are eligible for government programs such as Medicare or Medicaid may be able to get Keytruda at a lower cost.
The Importance of Access to Keytruda
Access to Keytruda is crucial for patients with cancer who may not have other treatment options. According to a study published in the Journal of Clinical Oncology, Keytruda has been shown to improve overall survival rates for patients with certain types of cancer.
"The cost of cancer treatment is a significant burden for many patients," said Dr. Julie Vose, a medical oncologist at the University of Nebraska Medical Center. "Co-pay assistance programs like the one offered by Merck can help make these treatments more affordable and accessible to patients who need them."
Key Takeaways
* The average wholesale price of Keytruda is around $12,500 per month.
* Merck offers a co-pay assistance program to help eligible patients pay for their co-pay.
* Patients must meet certain criteria to be eligible for co-pay assistance.
* Other options for affording Keytruda include patient assistance programs, non-profit organizations, and government programs.
Frequently Asked Questions
1. Q: How much does Keytruda cost per month?
A: The average wholesale price of Keytruda is around $12,500 per month.
2. Q: What is the co-pay for Keytruda?
A: The co-pay for Keytruda can range from $10 to $20 per prescription, depending on the patient's insurance coverage.
3. Q: How do I apply for co-pay assistance?
A: Patients can apply for co-pay assistance through the Merck Patient Assistance Program website or by calling 1-877-888-4231.
4. Q: Are there other options for affording Keytruda?
A: Yes, other options include patient assistance programs, non-profit organizations, and government programs.
5. Q: Why is access to Keytruda important for patients with cancer?
A: Access to Keytruda is crucial for patients with cancer who may not have other treatment options.
Sources
1. DrugPatentWatch.com. (2022). Pembrolizumab (Keytruda) - Average Wholesale Price (AWP).
2. Merck. (2022). Keytruda (pembrolizumab) - Co-Pay Assistance Program.
3. Journal of Clinical Oncology. (2020). Pembrolizumab in patients with advanced melanoma: a randomized, double-blind, phase 3 trial.
4. Cancer Financial Assistance Coalition (CFAC). (2022). Financial Assistance for Cancer Patients.
5. Patient Access Network (PAN) Foundation. (2022). Financial Assistance for Cancer Patients.
Note: The prices and information mentioned in this article are subject to change and may not reflect the current market prices or information.